It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Discover precise insights into brain neurochemistry with Sygnature Discovery's in vivo microdialysis and cOFM services. With over 20 years of expertise, we design bespoke studies that reveal how compounds modulate neurotransmitter systems in health and disease. Using UHPLC/HPLC with electrochemical detection or mass spectrometry, we deliver robust PK/PD data to support confident CNS decision making.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
AI Meets Expertise: A hybrid Workflow For Modern Target ID | QIAGEN & Sygnature
In drug discovery, generating targets is no longer the challenge.
The real question is how to identify the few worth investing months of research and significant resources to pursue.
Hear expert perspectives on how AI, pathway analysis and scientific expertise are shaping modern target identification.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Nuclear Magnetic Resonance (NMR) spectroscopy is one of the most powerful techniques available for studying biomolecules in solution. Unlike many analytical methods, NMR can provide detailed information on protein structure, stability, dynamics, and molecular interactions under near-physiological conditions.
At Sygnature Discovery, we have extensive experience producing isotope-labeled proteins to support NMR studies. Combined with specialist NMR expertise and access to leading NMR facilities, we can support a range of applications from protein quality assessment through to protein-ligand interaction analysis and structural characterization.
What Is NMR?
NMR exploits the magnetic properties of certain atomic nuclei, including hydrogen (¹H), nitrogen (¹⁵N), and carbon (¹³C). When placed in a strong magnetic field and exposed to radiofrequency pulses, these nuclei generate signals that provide detailed information about their molecular environment.
Since its development in the mid-20th century, advances in superconducting magnet technology and data processing have transformed NMR into a versatile tool for investigating proteins, nucleic acids, carbohydrates, and small molecules.
For many protein-focused applications, isotopically labeled proteins containing ¹⁵N and ¹³C are produced to improve sensitivity and enable residue-specific analysis. These labeled proteins are typically generated through recombinant expression in bacterial systems using isotope-enriched growth media.
Assessing Protein Quality and Stability
One of the most valuable applications of NMR is the rapid assessment of protein quality.
For unlabeled proteins, one-dimensional (1D) proton NMR spectra can provide information about whether a protein is folded or unfolded. Well-folded proteins produce highly dispersed resonances, whereas unfolded proteins exhibit a much narrower range of signals.
When ¹⁵N-labeled proteins are available, two-dimensional (2D) NMR experiments provide significantly greater detail. These spectra can act as molecular fingerprints, allowing scientists to assess protein integrity, stability, and conformational changes with residue-level resolution.
This capability makes NMR a valuable quality-control tool during protein production and characterization workflows.
Figure 1. 1D and 2D-NMR spectra of folded (black) and unfolded proteins (red). A) According to the nature of the protons, they experience a specific frequency in the H dimension; see highlighted regions on top of the figure. B) Increasing the dimensionality of the amide region (H/N correlation spectrum).
Characterizing Protein-Ligand Interactions
NMR is uniquely suited to studying molecular interactions in solution and has become an important technique in drug discovery, particularly for fragment screening and hit validation.
One of its key strengths is the ability to detect interactions across a wide range of affinities while providing atomic-level information about binding events.
Two complementary approaches are commonly used.
1.Ligand-Observed NMR
In ligand-observed experiments, the small molecule acts as the reporter molecule.
These methods do not require isotope-labeled protein and can be applied to proteins of virtually any size.
Common techniques include:
Saturation Transfer Difference (STD) NMR
WaterLOGSY
¹⁹F-based NMR assays
These approaches are widely used to identify and confirm binding interactions during early-stage drug discovery and fragment screening campaigns (Figure 2).
Figure 2. Methodologies to explore binding process between small molecules and proteins. On the left panel is the 3D representation of the molecules involve in the interaction. On the right panel is the graphical representation of the expected resonances for no binders and binders, for each methodology.
2. Protein-Observed NMR
Protein-observed experiments use ¹⁵N- or ¹³C-labeled proteins and provide more detailed information about the interaction (Figure 3).
By monitoring changes in individual resonances during ligand titration experiments, it is possible to:
Identify binding regions on the protein
Monitor transient and stable interactions
Estimate binding affinity
Support structural modeling of protein-ligand complexes
Importantly, NMR can evaluate interactions with a wide range of binding partners, including small molecules, peptides, proteins, nucleic acids, carbohydrates, and lipids.
Figure 3. Extracting structural information of protein ligand interactions from NMR. A) Example of ligand titrations followed by H/N-2D NMR spectra. Trend of the residues involved in the interaction are shown by black arrows. B) 3D reconstruction model based on CSP restraints obtained from A). From Maya-Martinez et al. Front. Microbiol. 18(9) (2019)
The Value of NMR in Drug Discovery
NMR provides a unique combination of structural, biophysical, and interaction data that can support multiple stages of a discovery program.
Applications include:
Protein quality control
Stability assessment
Fragment screening
Hit validation
Binding-site characterization
Dynamic conformational analysis
Structural biology studies
By revealing how proteins behave and interact in solution, NMR can help researchers gain confidence in candidate molecules and make better-informed decisions during drug discovery.
Conclusion
NMR remains one of the most versatile techniques available for characterizing proteins and molecular interactions. Whether assessing protein quality, validating ligand binding, or investigating molecular mechanisms, NMR provides insights that are often difficult to obtain through other analytical approaches.
Combined with expertise in recombinant protein production and isotope labeling, NMR can play a valuable role in addressing challenging protein science and drug discovery questions.
References
C. Raingeval, et al., 1D NMR WaterLOGSY as an efficient method for fragment-based lead discovery. J. Enzyme Inhib. Med. Chem. 34, 1218–1225 (2019).
R. S. Norton, E. W. W. Leung, I. R. Chandrashekaran, C. A. MacRaild, Applications of 19F-NMR in fragment-based drug discovery. Molecules 21 (2016).
M. P. Williamson, Using chemical shift perturbation to characterise ligand binding. Prog. Nucl. Magn. Reson. Spectrosc. 73, 1–16 (2013).
Maya-Martinez, et al., Recognition of Peptidoglycan Fragments by the Transpeptidase PBP4 From Staphylococcus aureus. Front. Microbiol. 18(9) (2019)